Among healthy men aged 70–80 years with high-risk nonmetastatic prostate cancer (defined as prostate cancer with no evidence of metastasis (N0 or Nx, M0 or Mx) and at least one of the following three criteria: Gleason score 8–10, local clinical stage T3, or prostate-specific antigen (PSA) 20–49 ng /mL), there was a significant increase in the use of treatment with curative intent, from 10% in 2001 to almost 50% in 2012. The gene discussed is KLK3; the disease is prostate cancer.